Funding and Research Opportunities

The following funding opportunity announcements from the NHLBI or other components of the National Institutes of Health, might be of interest:

Notices

NIH/AHRQ Application Submission/Resubmission Policy
(NOT-OD-18-197) Office of the Director, NIH

NIH Offers Assistance to Phase II HHS SBIR and STTR Awardees through the NIH Commercialization Accelerator Program (CAP) 2018-2019
(NOT-OD-18-213) Office of the Director, NIH

Update on NIHs Next Generation Researchers Initiative (NGRI) Policy on Early Established Investigators (EEIs)
(NOT-OD-18-214) Office of the Director, NIH

NIAID T32 and T35 Training Grants Maximum Number of Trainee Slots
(NOT-AI-18-044)
National Institute of Allergy and Infectious Diseases

Notice of Change of Key Dates to RFA-HL-18-023 "Stimulating Access to Research in Residency (StARR) (R38)"
(NOT-HL-18-639)
National Heart, Lung, and Blood Institute

Notice Announcing Partnership Opportunity for Device-Based Clinical Studies Issued for the Stimulating Peripheral Activity to Relieve Conditions Program
(NOT-RM-18-019)
Office of Strategic Coordination (Common Fund)

Notice of Availability of Administrative Supplements for Tissue Chip Consortium Awardees: Development of Tissue Chips to Model Nociception, Opioid Addiction and Overdose
(NOT-TR-18-027)
National Heart, Lung, and Blood Institute

Notice of Modification to RFA-TR-18-020 Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN) (U54 Clinical Trial Optional)
(NOT-TR-18-030)
National Center for Advancing Translational Sciences

Requests for Applications

Molecular Atlas of Lung Development Program (LungMAP) Phase 2 Research Centers (U01- Clinical Trial Not Allowed)
(RFA-HL-19-020)
National Heart, Lung, and Blood Institute

Molecular Atlas of Lung Development Program (LungMAP) Phase 2 - Human Tissue Core (U01- Clinical Trial Not Allowed)
(RFA-HL-19-021)
National Heart, Lung, and Blood Institute

Molecular Atlas of Lung Development Program (LungMAP) Phase 2 - Data Coordinating Center (U24- Clinical Trial Not Allowed)
(RFA-HL-19-022)
National Heart, Lung, and Blood Institute

Development of Cell and Tissue Platforms to Detect Adverse Biological Consequences of Somatic Cell Genome Editing (U01 Clinical Trial Not Allowed)
(RFA-RM-18-022)
Office of Strategic Coordination (Common Fund)

Innovative Technologies to Deliver Genome Editing Machinery to Disease-relevant Cells and Tissues (UG3/UH3 Clinical Trial Not Allowed)
(RFA-RM-18-023)
Office of Strategic Coordination (Common Fund)

Expanding the Human Genome Engineering Repertoire (U01 Clinical Trial Not Allowed)
(RFA-RM-18-024)
Office of Strategic Coordination (Common Fund)

Innovative Technologies to Non-Invasively Monitor Genome Edited Cells In Vivo (UH2/UH3 Clinical Trial Not Allowed)
(RFA-RM-18-025)
Office of Strategic Coordination (Common Fund)

Genome Sequencing Center for the Gabriella Miller Kids First Pediatric Research Program (U24 Clinical Trial Not Allowed)
(RFA-RM-18-030)
Office of Strategic Coordination (Common Fund)